United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Tredje AP fonden

Tredje AP fonden reduced its stake in United Therapeutics Co. (NASDAQ:UTHR) by 1.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,359 shares of the biotechnology company’s stock after selling 142 shares during the period. Tredje AP fonden’s holdings in United Therapeutics were worth $2,981,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Norges Bank acquired a new position in United Therapeutics in the fourth quarter valued at $100,519,000. LSV Asset Management boosted its holdings in shares of United Therapeutics by 82.5% in the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after acquiring an additional 436,851 shares during the period. Swedbank AB purchased a new position in shares of United Therapeutics during the first quarter worth approximately $97,316,000. Nordea Investment Management AB increased its holdings in shares of United Therapeutics by 677.6% in the 1st quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock valued at $72,422,000 after acquiring an additional 262,222 shares during the period. Finally, Avidity Partners Management LP purchased a new stake in United Therapeutics in the 4th quarter valued at $52,158,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. LADENBURG THALM/SH SH lowered shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. Wells Fargo & Company upped their price objective on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. UBS Group lifted their target price on United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research note on Monday, July 8th. TD Cowen upped their price target on United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $400.00 price objective on shares of United Therapeutics in a research report on Thursday, August 1st. One analyst has rated the stock with a sell rating, three have given a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $350.36.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 7,802 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $345.41, for a total transaction of $2,694,888.82. Following the completion of the transaction, the chief financial officer now directly owns 3,210 shares in the company, valued at approximately $1,108,766.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $315.97, for a total transaction of $1,137,492.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $41,076.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James Edgemond sold 7,802 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $345.41, for a total value of $2,694,888.82. Following the transaction, the chief financial officer now owns 3,210 shares of the company’s stock, valued at $1,108,766.10. The disclosure for this sale can be found here. Insiders sold 110,922 shares of company stock valued at $36,541,398 in the last 90 days. 12.50% of the stock is currently owned by insiders.

United Therapeutics Trading Up 2.6 %

Shares of United Therapeutics stock opened at $351.33 on Friday. The company has a 50-day moving average of $338.00 and a two-hundred day moving average of $289.96. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $366.08. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. The stock has a market cap of $15.63 billion, a PE ratio of 16.61, a price-to-earnings-growth ratio of 1.25 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). The firm had revenue of $714.90 million during the quarter, compared to analysts’ expectations of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The business’s revenue for the quarter was up 19.8% on a year-over-year basis. During the same period in the previous year, the business earned $5.24 earnings per share. On average, research analysts anticipate that United Therapeutics Co. will post 24.86 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.